Mizuho analyst Vamil Divan notes that Evolus issued a statement addressing comments in the Korean media related to ongoing litigation between their partner Daewoong and competitor Medytox. While it appears Medytox has leaked some confidential staff attorney briefings to the Korean press, it is not clear how meaningful this information actually is as it relates to the judge's initial determination on the case or the ITC's crucial final decision, he notes. Divan continues to see value in Evolus at current levels given the progress it is making with Jeuveau's launch in the facial aesthetics market, but appreciates new investors in particular may remain concerned with the legal overhang. The analyst has a Buy rating and a $20 price target on the shares.